LabGenomics Largest Shareholder Purchases Additional Shares..."Enhancing Shareholder Value"

LabGenomics's largest shareholder, Luhagalacticos, has purchased additional shares to strengthen responsible management and enhance shareholder value.

According to LabGenomics on July 15, Luhagalacticos acquired an additional 1,240,100 LabGenomics shares through open market purchases. As a result, its holdings increased from 13,893,425 to 15,133,525 shares, and its ownership stake expanded from 18.7% to 20.38%. The total value of this additional purchase amounts to 1 billion won.

Recently, LabGenomics has been expanding its high value-added diagnostics business, focusing on its CLIA lab in the United States. The company is strengthening a highly profitable portfolio of tests, such as next-generation sequencing (NGS), cancer diagnostics, and genetic testing, leveraging its diagnostic infrastructure in the US. In Korea, LabGenomics is undertaking the restructuring of its business portfolio by divesting non-core businesses, shifting toward a profitability-driven structure.

In particular, the company is expanding its cancer diagnostics test lineup centered on its US subsidiary, IMD (Integrated Molecular Diagnostics), and is preparing to expand its high-value diagnostic services by utilizing its local hospital network in the United States. LabGenomics plans to extend its business focus from conventional diagnostic testing to high value-added precision diagnostics, aiming to further increase growth and profitability in the US market.

A representative of LuhaPE stated, "This additional purchase demonstrates the largest shareholder's confidence in LabGenomics' US CLIA lab-based growth strategy and path toward improved profitability," adding, "As the largest shareholder, we will fulfill responsible management and continue to support the company so that its mid- and long-term corporate value is properly recognized by the market."

This content was produced with the assistance of AI translation services.